Fresenius Medical Care : The next black swan
>Guidance cut due to lack of staff and cost inflation - On the back of increased headwinds from the US labour market (lack of nurses translates into slower patient growth than possible) as well as global inflation, Fresenius Medical Care lowered its guidance for FY 2022 for revenue growth to the low end of the previously guided low-to mid-single digit growth range. Due to negative operating leverage as well as high cost inflation, net income is expected to decline in ...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.